Last $7.36 USD
Change Today +0.40 / 5.75%
Volume 72.5K
RGLS On Other Exchanges
As of 8:10 PM 04/22/14 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/11/13 - $12.89
52 Week Low
11/13/13 - $5.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

73 Employees
Last Reported Date: 02/28/14
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $600.0K
Chief Scientific Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 10:00 AM

Regulus Therapeutics Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 10:00 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Neil W. Gibson, Chief Scientific Officer.

Regulus Therapeutics Commences Dosing RG-101 in Healthy Volunteers in Phase I Study

Regulus Therapeutics Inc. announced that it has commenced dosing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 (miR-122) in healthy volunteer subjects in a Phase I clinical study. The primary objective of the study is to evaluate safety and tolerability of RG-101 and the secondary objectives are to evaluate pharmacokinetics, viral load reduction and any impact an oral direct-acting antiviral may have on the pharmacokinetics of RG-101. The Phase I clinical study of RG-101 will have four parts: (i) a single ascending-dose study in healthy volunteer subjects; (ii) a multiple-ascending dose study in healthy volunteer subjects; (iii) a single-dose drug-drug interaction study of RG-101 in combination with an approved oral direct-acting antiviral ("DAA") in healthy volunteer subjects; and (iv) a single-dose study in HCV patients to assess the safety and viral load reduction, which is designed to demonstrate human proof-of-concept. Up to approximately 100 healthy volunteer subjects and HCV patients are planned to be enrolled in the Phase I study, which is being conducted in the Netherlands.

Regulus Seeks Acquisitons

Regulus Therapeutics Inc. (NasdaqGM:RGLS) seeks acquisitions. Regulus Therapeutics may also use a portion of the net proceeds received from a follow-on offering of common stock to in-license, acquire or invest in complementary microRNA businesses, technologies, products or assets.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $7.36 USD +0.40

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.26 AUD 0.00
Enzon Pharmaceuticals Inc $0.98 USD +0.0124
Galena Biopharma Inc $2.08 USD +0.23
Silence Therapeutics PLC 261.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$16.67 CAD +0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.9x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at